NEW YORK — Scott Gottlieb, the commissioner of the Food and Drug Administration, is a free-market proponent in a fervently anti-regulatory administration who is trying to lower drug prices by expanding the regulatory reach of the agency.

Speaking Wednesday at CNBC’s Healthy Returns conference, Gottlieb criticized branded drug companies, distributors, and pharmacy benefit managers for practices that reduce competition and restrict market access to generic drugs, including biosimilars.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy